{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:31:58Z","timestamp":1759336318020},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s40265-014-0193-9","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T13:43:01Z","timestamp":1394199781000},"page":"415-422","source":"Crossref","is-referenced-by-count":14,"title":["Spleen Tyrosine Kinase Inhibitors for Rheumatoid Arthritis: Where Are We Now?"],"prefix":"10.1007","volume":"74","author":[{"given":"Ian C.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,8]]},"reference":[{"key":"193_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1590\/S1516-31802010000500013","volume":"128","author":"JA Singh","year":"2010","unstructured":"Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2010;128:309\u201310.","journal-title":"Sao Paulo Med J"},{"key":"193_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/BOR.0b013e3282fa13ee","volume":"20","author":"J Stanczyk","year":"2008","unstructured":"Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20:257\u201362.","journal-title":"Curr Opin Rheumatol"},{"key":"193_CR3","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/rheumatology\/kes367","volume":"52","author":"V Kelly","year":"2013","unstructured":"Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology. 2013;52:1155\u201362.","journal-title":"Rheumatology"},{"key":"193_CR4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002281-200405000-00011","volume":"16","author":"SE Sweeney","year":"2004","unstructured":"Sweeney SE, Firestein GS. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16:231\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"193_CR5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","volume":"13","author":"JSC Arthur","year":"2013","unstructured":"Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679\u201392.","journal-title":"Nat Rev Immunol"},{"key":"193_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","volume":"60","author":"SB Cohen","year":"2009","unstructured":"Cohen SB, Cheng T-T, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60:335\u201344.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"193_CR7","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2009.119479","volume":"69","author":"D Hammaker","year":"2010","unstructured":"Hammaker D, Firestein GS. \u201cGo upstream, young man\u201d: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69(Suppl 1):i77\u201382.","journal-title":"Ann Rheum Dis"},{"key":"193_CR8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273\u201387.","journal-title":"Immunol Rev"},{"key":"193_CR9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"193_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"193_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.jbchem.a002970","volume":"130","author":"K Sada","year":"2001","unstructured":"Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130:177\u201386.","journal-title":"J Biochem"},{"key":"193_CR12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clim.2007.03.543","volume":"124","author":"PR Pine","year":"2007","unstructured":"Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124:244\u201357.","journal-title":"Clin Immunol"},{"key":"193_CR13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337\u201345.","journal-title":"Arthritis Rheum"},{"key":"193_CR14","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:3309\u201318.","journal-title":"Arthritis Rheum"},{"key":"193_CR15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","volume":"363","author":"ME Weinblatt","year":"2010","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363:1303\u201312.","journal-title":"N Engl J Med"},{"key":"193_CR16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/annrheumdis-2013-eular.253","volume":"72","author":"PC Taylor","year":"2013","unstructured":"Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B, et al. Oskira-4: a phase IIB randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2013;72:66.","journal-title":"Ann Rheum Dis"},{"key":"193_CR17","first-page":"455","volume":"65","author":"P Dawes","year":"2013","unstructured":"Dawes P, Dimic A, Genovese MC, van der Heijde D, Jenkins M, O\u2019Brien C, et al. Oskira-2: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs [abstract]. Arthritis Rheum. 2013;65:455.","journal-title":"Arthritis Rheum"},{"key":"193_CR18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/art.37820","volume":"65","author":"M Genovese","year":"2013","unstructured":"Genovese M, van der Heijde D, Keystone E, Spindler A, Benhamou C, Kavanaugh A, et al. Oskira-3: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to a tumor necrosis factor-a antagonist [abstract]. Arthritis Rheum. 2013;65:456.","journal-title":"Arthritis Rheum"},{"key":"193_CR19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.37711","volume":"65","author":"M Weinblatt","year":"2013","unstructured":"Weinblatt M, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Oskira-1: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2013;65:1793.","journal-title":"Arthritis Rheum"},{"key":"193_CR20","first-page":"583","volume":"32","author":"F Wolfe","year":"2005","unstructured":"Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol. 2005;32:583\u20139.","journal-title":"J Rheumatol"},{"key":"193_CR21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3899\/jrheum.120923","volume":"40","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013;40:369\u201378.","journal-title":"J Rheumatol"},{"key":"193_CR22","first-page":"2594","volume":"63","author":"A Kavanaugh","year":"2011","unstructured":"Kavanaugh A, Weinblatt ME, Genovese MC, Musser TK, Grossbard EB, Magilavy DB, et al. Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis analysis of clinical trial data from up to 2\u00a0years of exposure [abstract]. Arthritis Rheum. 2011;63:2594.","journal-title":"Arthritis Rheum"},{"key":"193_CR23","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2010-09-305284","volume":"117","author":"S Kazerounian","year":"2011","unstructured":"Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, et al. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood. 2011;117:4658\u201366.","journal-title":"Blood"},{"key":"193_CR24","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/ket225","volume":"52","author":"JS Nijjar","year":"2013","unstructured":"Nijjar JS, Tindell A, McInnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology. 2013;52:1556\u201362.","journal-title":"Rheumatology"},{"key":"193_CR25","doi-asserted-by":"crossref","unstructured":"Okamoto H, Kobayashi A. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2011;364:83\u20134 (author reply 4).","DOI":"10.1056\/NEJMc1012187"},{"key":"193_CR26","doi-asserted-by":"crossref","unstructured":"Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2013 (Epub ahead of print).","DOI":"10.1136\/annrheumdis-2012-203116"},{"key":"193_CR27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","volume":"14","author":"Y He","year":"2013","unstructured":"He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298.","journal-title":"BMC Musculoskelet Disord"},{"key":"193_CR28","doi-asserted-by":"crossref","unstructured":"Gaujoux-Viala C, Nam J, Ramiro S, Landew\u00e9 R, Buch MH, Smolen JS, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 (Epub ahead of print).","DOI":"10.1136\/annrheumdis-2013-204588"},{"key":"193_CR29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/clpt.2011.278","volume":"91","author":"DL Scott","year":"2012","unstructured":"Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91:30\u201343.","journal-title":"Clin Pharmacol Ther"},{"key":"193_CR30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.berh.2007.02.007","volume":"21","author":"T Pincus","year":"2007","unstructured":"Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol. 2007;21:601\u201328.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"193_CR31","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2010.146043","volume":"70","author":"MU Rahman","year":"2011","unstructured":"Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16\u00a0years. Ann Rheum Dis. 2011;70:1631\u201340.","journal-title":"Ann Rheum Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0193-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0193-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T06:43:38Z","timestamp":1565246618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0193-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0193-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}